Contact Us

•health professionals

TEXT SIZE

ASH 2007 WEBCAST We are pleased to present these overviews of the 49th Annual American Society of Hematology Meeting (ASH) that was held in Atlanta, Georgia from December 8-11, 2007.

print   share |

Elijah Alexander: ASH 2007: A Patient's Perspective
	Elijah Alexander Former NFL lineman and Myeloma Patient shares his reactions on attending ASH for the first time

---

Dr. Kyle: An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
	Dr. Robert Kyle Mayo Clinic Rochester, Minnesota Chair, IMF Scientific Advisory Board

---

Dr. Durie: An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
	Dr.Brian G.M. Durie Cedars Sinai Cancer Center Los Angeles, California Chair of the International Myeloma Foundation

---

Dr. San Miguel: A Review of Novel Agents Presented at the 49th Annual American Society of Hematology Meeting (ASH) 2007
	Dr. Jesús San Miguel Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors

---

Dr. Gertz - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
	Morie A Gertz, MD Mayo Clinic Rochester, Minnesota Member, IMF Board of Scientific Advisors

---

Dr. Jagannath: ASH 2007: New Drug Combinations as Induction Therapy
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, NY Member, IMF Board of Scientific Advisors

---

Dr. Boccadoro - An Overview of the 49th Annual American Society of Hematology Meeting (ASH) 2007
	Mario Boccadoro, MD Divisione Universitaria di Ematologia Ospedale Molinette Torino, Italy Member, IMF Board of Scientific Advisors

---

ASH 2007 INTERNATIONAL WEBCASTS
	We are pleased to be able to present overviews of ASH 2007 in French, Spanish, German, Italian, Turkish, and Czech.

---

Dr. San Miguel - A Phase 3 Study Comparing BortezomibMelphalanPrednisone (VMP) with MelphalanPrednisone (MP) in Newly Diagnosed Multiple Myeloma.
	Dr. Jesús San Miguel Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors

---

Dr. Rajkumar - A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group
	S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota Member, IMF Board of Scientific Advisors

---

Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
	Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors

---

Dr. Kumar - Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma
	Shaji Kumar, MD Mayo Clinic Rochester, MN

---

Dr. Palumbo - Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m in Elderly Newly Diagnosed Patients: An Interim Analysis
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy Member,IMF Board of Scientific Advisors

---

Dr. Palumbo - A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens
	Antonio Palumbo, MD Ospedale Molinette Torino, Italy Member,IMF Board of Scientific Advisors

---

Dr. Jagannath - A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, New York Member, IMF Board of Scientific Advisors

---

Dr. Reeder - Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls
	Craig B. Reeder, MD Mayo Clinic Scottsdale, Arizona

---

Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
	Heinz Ludwig, MD Wilhelminenspital der Stadt Wein Vienna, Austria Member, IMF Board of Scientific Advisors

---

Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
	Jeffrey A. Zonder, MD Karmanos Cancer Institute Detroit, Michigan

---

Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
	Anders Waage, MD University Hospital Trondheim, Norway

---

Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
	Jesús San Miguel, MD Hospital Clinico Universitario Universidad de Salamanca Salamanca, Spain Member, IMF Board of Scientific Advisors

---

Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
	Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center New York, NY Member, IMF Board of Scientific Advisors

---

Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
	Joan Bladé, MD Hospital Clinic Hematology Barcelona, Spain Member, IMF Board of Scientific Advisors

---

Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
	Faith E. Davies, MD The Royal Marsden NHS Foundation Trust Sutton, Surrey, UK Member, IMF Board of Scientific Advisors

---

Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma
	Robert Z. Orlowski, MD MD Anderson Cancer Center Houston, Texas

---

Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
	Andrzej Jakubowiak, MD University of Michigan Cancer Center Ann Arbor, MI

---

Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
	Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors

---

Dr. Orlowski - Safety and Antitumor Efficacy of the Proteasome Inhibitor Carfilzomib (PR-171) Dosed for Five Consecutive Days in Hematologic Malignancies: Phase 1 Results
	Robert Z. Orlowski, MD MD Anderson Cancer Center Houston, Texas

---

Dr. Ocio - Antimyeloma Efficacy of Plitidepsin (Aplidin): From Bench to the Bedside
	Enrique M. Ocio, MD Hospital Universitario de Salamanca Salamanca, Spain

---

Dr. Richardson - An Overview of Studies of the New Agent Perifosine (KRX-0401) Alone and in Combination for Patients with Relapsed/Refractory Multiple Myeloma
	Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors

---

Dr. Richardson - Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma
	Paul Richardson, MD Jerome Lipper Myeloma Center Dana Farber Cancer Institute Boston, MA Member, IMF Board of Scientific Advisors

---

Dr. Ocio - Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model
	Enrique M. Ocio, MD Hospital Universitario de Salamanca Salamanca, Spain

---

Dr. Dispenzieri - Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma
	Angela Dispenzieri, MD Mayo Clinic Rochester, Minnesota

---

Dr. Davies - Aminopeptidase Inhibition as a Targeted Treatment Strategy in Myeloma
	Faith E. Davies, MD The Royal Marsden NHS Foundation Trust Sutton, Surrey, UK Member, IMF Board of Scientific Advisors

---

Dr. Zonder - Phase I Trial of HuLuc63 in Multiple Myeloma
	Jeffrey A. Zonder, MD Karmanos Cancer Institute Detroit, Michigan

---

Dr. Aggarwal: Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: Results of a phase 1/2 study
	Bahrat Aggarwal, PhD MD Anderson Cancer Center Houston, Texas

---

Dr. Harousseau - VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial
	Jean Luc Harousseau, MD Hematologie Clinique CHU Hotel Dieu Nantes, France Member, IMF Board of Scientific Advisors

---

Dr. Bruno - An Update of a Comparison of Nonmyeloablative Allografting with Autografting for Newly Diagnosed Myeloma
	Benedetto Bruno, MD, PhD San Giovanni Battista Hospital University of Torino Torino, Italy

---

Dr. Hajek - Consolidation Therapy Based on Conventional Chemotherapy and Corticoids Do Not Provide Therapeutic Advantage for Newly Diagnosed Patients after Autologous Transplantation
	Roman Hajek, MD University Hospital Brno Brno, Czech Republic Member, IMF Board of Scientific Advisors

---

Dr. Tosi - Superiority of Double over Single Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma and Prognostic Impact of Complete Response: Final Analysis of Bologna 96 Study
	Patrizia Tosi, MD Seràgnoli Institute of Hematology Bologna, Italy

---

Dr. Beksac - Amplitude of Response, Early Mobilization (M) and Pre-Autologous Transplant (ASCT) Use of Bortezomib (V) and/or Thalidomide(T) Are Predictors of Longer Progression Free (PFS) and/or Overall Survival (OS) in Myeloma
	Meral Beksac, MD Ankara University Ibn Sina Hospital Ankara, Turkey Member, IMF Board of Scientific Advisors

---

Dr. Ladetto - Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients
	Marco Ladetto, MD Divisione Universitaria di Ematologia L'università di Torino Torino, Italy

---

Dr. Tosi - Bortezomib (Velcade)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
	Patrizia Tosi, MD Seràgnoli Institute of Hematology Bologna, Italy

---

Dr. De la Rubia - Toxicity and Early Response after Single Daily Dose of Intravenous Busulfan and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Session Type: Publication Only
	Javier de la Rubia, MD University Hospital La Fe Valencia, Spain

---

Dr. Bladé - Tandem Autologous Transplant Versus Reduced Intensity Conditioned Allogeneic Transplant (Allo-RIC) as Second Intensification in Chemosensitive Patients with Multiple Myeloma (MM) Not Achieving Complete Remission (CR) or Near-CR with a First Autologous Transplant. Results from a Spanish PETHEMA/GEM Study.
	Joan Bladé, MD Hospital Clinic Hematology Barcelona, Spain Member, IMF Board of Scientific Advisors

---

Dr. Einsele - An Overview of Two Studies Conducted at the University Clinic of Würzburg
	Hermann Einsele, MD University Clinic of Würzburg Würzburg, Germany Member, IMF Board of Scientific Advisors

---

Dr. Liebisch - Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
	Peter Liebisch, MD University Hospital of Ulm Ulm, Germany

---

Dr. Avet-Loiseau - High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients
	Herve Avet-Loiseau, MD Institut de Biologie Nantes, France Member, IMF Board of Scientific Advisors

---

Dr. Sezer - The Bone Resorption Marker Serum-ICTP and the Circulating Proteasome Levels Separate ISS-Stages 1-3 and Are the Most Powerful Prognostic Factors for Overall Survival in Newly Diagnosed Symptomatic Multiple Myeloma
	Orhan Sezer, MD Medizinische Klinik und Poliklinik II Berlin, Germany Member, IMF Board of Scientific Advisors

---

Dr. Durie - Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.
	Brian G.M. Durie, MD Cedars Sinai Comprehensive Cancer Center Los Angeles, California Chairman, International Myeloma Foundation

---

Dr. Kyle - Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition
	Robert A. Kyle, MD Mayo Clinic Rochester, Minnesota Chair, IMF Board of Scientific Advisors

---

Dr. Kumar - Improving Survival in Multiple Myeloma: Impact of Novel Therapies
	Shaji Kumar, MD Mayo Clinic Rochester, MN

---

Dr. Jakubowiak - Targeted Therapy Against Clonogenic Myeloma Cells with Iodine I-131 Tositumomab (Bexxar™).
	Andrzej Jakubowiak, MD University of Michigan Cancer Center Ann Arbor, MI

---

Dr. Kyle - Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.
	Robert A. Kyle, MD Mayo Clinic Rochester, Minnesota Chairman, IMF Board of Scientific Advisors

---

Dr. Goldschmidt - Angiogenic Signature of Multiple Myeloma Determined by Gene Expression Profiling
	Hartmut Goldschmidt, MD Medizinischen Universitätsklinik und Poliklinik V University of Heidelberg Heidelberg, Germany Member, IMF Board of Scientific Advisors

---